Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


French limit conditions and prices for heart leads

This article was originally published in Clinica

Executive Summary

Manufacturers of leads used in implantable heart stimulation devices, such as pacemakers, have until March 2 to comment on two proposals just published in the French Journal officiel that will impact conditions for reimbursement and the prices they can charge. The first of the two proposals, drafted by the French commission responsible for the evaluation of healthcare products and services, CEPP, lists the various conditions of use which must be met when the various leads are implanted. The second, drafted by the healthcare products pricing committee, the CEPS, proposes upper limits of prices that can be charged and reimbursed for these different types of leads, which are set at E540 ($654) for most leads except for those used in transvenous stimulation, which are set at E850. The proposals were published in the JO on January 31.

You may also be interested in...

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts